Thyroid cancers harboring genetic rearrangements involving NTRK1/3 (~2% of PTC) can respond to treatment with TRK inhibitors, including FDA-approved larotrectinib and entrectinib (72, 93–95). This evidence concerns the gene NTRK1 and thyroid cancer.